Clinical Trial

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-25.
Trial Details
NCT Number NCT06389526
Lead Sponsor Coherus Oncology, Inc.
Conditions Advanced or Metastatic Solid Tumors
Enrollment 48 participants
Start Date 2025-02-15
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19